评估治疗多发性硬化症基因治疗的早期经济可行性,使用风险调整的评估框架.
Attila Imre1,2,3, Balázs Nagy1,2,3, Rok Hren3,4,5
1Center for Health Technology Assessment, Semmelweis University, 1085 Budapest, Hungary.
Healthcare (Basel, Switzerland)
|March 14, 2026
概括
针对多发性硬化症 (MS) 的新型基因疗法IMMUTOL的财务可行性表明,如果没有降低成本或外部支持,商业开发是没有吸引力的. 当前的定价模式可能与先进疗法的经济现实不一致.
科学领域:
- 生物技术是生物技术.
- 基因治疗 基因治疗
- 药物经济学 药物经济学
背景情况:
- 多发性硬化症 (MS) 带来了重大的临床和经济负担.
- 现有的疾病修饰疗法需要终身治疗,而不能达到免疫耐受性.
- 伊姆托尔是一种新型耐受性基因疗法,旨在诱导MS的持久缓解.
研究的目的:
- 评估IMMUTOL的早期财务可行性.
- 评估开发一种用于MS的新基因疗法的经济可行性.
主要方法:
- 使用风险调整后的净当前价值 (rNPV) 模型.
- 合并的开发,运营和制造成本.
- 分析了市场动态,收入预测和成功概率.
- 进行单向,概率和场景分析,以检查不确定性.
主要成果:
- 基准案例分析预测了2238万美元的确定性rNPV.
- 概率分析表明,平均NPV为-99.4亿美元,其中70.2%的模拟结果为负值.
- 只有在治疗价格高 (150万美元) 和制造成本低 (200,000美元) 的场景中才能实现正的rNPV.
结论:
- 在基于价值的定价和IMMUTOL的商业可行性之间存在结构性差距.
- 在没有大幅降低成本或外部财政支持的情况下,商业开发在经济上似乎没有吸引力.
- 这些发现突显了MS创新基因疗法的经济可持续性的挑战.
相关概念视频
Gene Therapy
27.9K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.9K
Microorganisms in Medicine and Therapeutics
1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
iPS Cell Differentiation
3.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.2K


